17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

FOR IMMEDIATE RELEASE

Sun Pharmaceutical announces USFDA approval to market generic Paraplatin® injection

Mumbai, September 23, 2008: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted an approval for the Abbreviated New Drug Application (ANDA) to market generic Paraplatin ®, carboplatin injection.

These generic versions of carboplatin 10mg/ml injections packed in 5 ml, 15ml and 45 ml single use vials are bio-equivalent to Paraplatin ® injections distributed by Bristol Myers Squibb Oncology/Virology.

Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma.

These strengths of Paraplatin® Injections have annual sales of approximately USD 45 million in the US.

Paraplatin ® is a registered trademark of Bristol Myers Squibb Company.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com